Neumora Therapeutics, Inc. (NMRA)
 NASDAQ: NMRA · Real-Time Price · USD
 3.010
 -0.010 (-0.33%)
  At close: Nov 3, 2025, 4:00 PM EST
2.880
 -0.130 (-4.32%)
  Pre-market: Nov 4, 2025, 5:40 AM EST
Neumora Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Neumora Therapeutics stock have a consensus rating of "Buy" and an average price target of $7.43, which forecasts a 146.84% increase in the stock price over the next year. The lowest target is $1.00 and the highest is $18.
Price Target: $7.43 (+146.84%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Neumora Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | 
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 | 
| Buy | 1 | 1 | 1 | 1 | 1 | 1 | 
| Hold | 4 | 4 | 4 | 4 | 3 | 2 | 
| Sell | 1 | 1 | 1 | 1 | 2 | 2 | 
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 | 
| Total | 8 | 8 | 8 | 8 | 8 | 8 | 
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date | 
|---|---|---|---|---|---|---|---|
|   Needham   | Needham | Strong Buy  Maintains  $6 → $8  | Strong Buy | Maintains | $6 → $8 | +165.78% | Oct 28, 2025 | 
|   Guggenheim   | Guggenheim | Hold → Strong Buy  Upgrades  $14  | Hold → Strong Buy | Upgrades | $14 | +365.12% | Oct 27, 2025 | 
|   JP Morgan   | JP Morgan | Hold → Sell  Downgrades  n/a  | Hold → Sell | Downgrades | n/a | n/a | Sep 16, 2025 | 
|   Mizuho   | Mizuho | Buy  Maintains  $4 → $5  | Buy | Maintains | $4 → $5 | +66.11% | Jul 16, 2025 | 
|   Needham   | Needham | Strong Buy  Reiterates  $5  | Strong Buy | Reiterates | $5 | +66.11% | May 13, 2025 | 
Financial Forecast
Revenue This Year
 n/a 
 Revenue Next Year
 3.64M 
 EPS This Year
 -1.44 
 from -1.53
EPS Next Year
 -1.03 
 from -1.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 
|---|---|---|---|---|---|
| High | n/a | 26.3M | |||
| Avg | n/a | 3.6M | |||
| Low | n/a | n/a | 
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - | 
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 
|---|---|---|---|---|---|
| High | -1.39 | -0.61 | |||
| Avg | -1.44 | -1.03 | |||
| Low | -1.51 | -1.59 | 
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - | 
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.